337 related articles for article (PubMed ID: 26179389)
1. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
[TBL] [Abstract][Full Text] [Related]
2. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke.
Floyd JS; Wiggins KL; Christiansen M; Dublin S; Longstreth WT; Smith NL; McKnight B; Heckbert SR; Weiss NS; Psaty BM
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):151-60. PubMed ID: 26547662
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
4. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
[TBL] [Abstract][Full Text] [Related]
5. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
7. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.
Sauer WH; Cappola AR; Berlin JA; Kimmel SE
Am J Cardiol; 2006 Mar; 97(5):651-4. PubMed ID: 16490431
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
10. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
[TBL] [Abstract][Full Text] [Related]
12. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
13. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.
Phung OJ; Schwartzman E; Allen RW; Engel SS; Rajpathak SN
Diabet Med; 2013 Oct; 30(10):1160-71. PubMed ID: 23663156
[TBL] [Abstract][Full Text] [Related]
14. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
[TBL] [Abstract][Full Text] [Related]
15. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
16. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
17. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
[TBL] [Abstract][Full Text] [Related]
18. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
[No Abstract] [Full Text] [Related]
20. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
